Amy Simon - 31 Mar 2024 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Role: Chief Medical Officer
Signature: By: /s/ Christine Bellon, Attorney-in-fact
Issuer symbol: BEAM
Transactions as of: 31 Mar 2024
Net transactions value: $0
Form type: 4
Filing time: 02 Apr 2024, 16:10:16 UTC
Previous filing: 02 Feb 2024
Next filing: 03 Apr 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BEAM	Common Stock	Award	$0	+27,500	+42%	$0.000000	93,747	31 Mar 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.
F2	Includes 363 shares and 415 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2023 and March 31, 2024, respectively.

Content

Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

Includes 363 shares and 415 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2023 and March 31, 2024, respectively.